Clinically, several antibodies against IL-23 p19 show good efficacy in moderate-to-severe psoriasis and psoriatic arthritis [4, 16] and it remains to be established whether IL-39 contributes to disease pathogenesis. The gene discussed is IL23A; the disease is psoriatic arthritis.